J.P. Morgan Believes Humana (HUM) Won’t Stop Here

In a report released yesterday, Lisa Gill from J.P. Morgan maintained a Buy rating on Humana (HUMResearch Report), with a price target of $540.00. The company’s shares closed last Thursday at $484.01, close to its 52-week high of $497.47.

According to TipRanks.com, Gill is a 5-star analyst with an average return of 18.5% and a 66.7% success rate. Gill covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Privia Health Group, and Option Care Health.

Currently, the analyst consensus on Humana is a Strong Buy with an average price target of $530.38, representing a 10.3% upside. In a report issued on July 14, Jefferies also maintained a Buy rating on the stock with a $560.00 price target.

See the top stocks recommended by analysts >>

Based on Humana’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $23.66 billion and net profit of $696 million. In comparison, last year the company earned revenue of $20.65 billion and had a net profit of $588 million.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.

Read More on HUM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More